$PDSB
PDS Biotechnology Corp

2021 Form 10-K Financial Statement

#000114036122012244 Filed on March 31, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.18M $1.530M $1.850M
YoY Change 46.33% 273.17% -38.33%
% of Gross Profit
Research & Development $11.25M $2.480M $2.061M
YoY Change 42.02% 83.7% 12.34%
% of Gross Profit
Depreciation & Amortization $5.357K $10.00K $0.00
YoY Change -65.68% 0.0% -100.0%
% of Gross Profit
Operating Expenses $21.44M $4.030M $3.907M
YoY Change 43.86% 128.98% -33.18%
Operating Profit -$21.44M -$3.907M
YoY Change 43.86% -33.18%
Interest Expense $4.350K $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$21.43M -$4.030M -$3.910M
YoY Change 44.37% -11.62% -32.0%
Income Tax -$4.500M
% Of Pretax Income
Net Earnings -$16.92M -$4.030M -$3.906M
YoY Change 13.95% -3.59% -32.09%
Net Earnings / Revenue
Basic Earnings Per Share -$0.66
Diluted Earnings Per Share -$0.66 -$180.7K -$206.2K
COMMON SHARES
Basic Shares Outstanding 25.60M 22.26M 15.36M
Diluted Shares Outstanding 25.60M

Balance Sheet

Concept 2021 2020 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $65.24M $28.80M $33.50M
YoY Change 126.54% 136.07% 92.53%
Cash & Equivalents $65.24M $28.84M $33.47M
Short-Term Investments
Other Short-Term Assets $1.598M $1.500M $400.0K
YoY Change 6.5% -34.78% -42.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $66.84M $30.34M $33.84M
YoY Change 120.59% 109.65% 86.63%
LONG-TERM ASSETS
Property, Plant & Equipment $357.7K $5.443K $9.345K
YoY Change -40.38% -74.14% -65.3%
Goodwill
YoY Change
Intangibles $2.974M $2.974M
YoY Change 0.0% 143.17%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $357.7K $553.1K $602.9K
YoY Change -40.38% 2527.66% -51.76%
TOTAL ASSETS
Total Short-Term Assets $66.84M $30.34M $33.84M
Total Long-Term Assets $357.7K $553.1K $602.9K
Total Assets $67.20M $30.89M $34.45M
YoY Change 117.47% 113.17% 77.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.309M $1.415M $1.560M
YoY Change -6.47% 18.16% 4.74%
Accrued Expenses $2.447M $1.735M $1.223M
YoY Change 28.77% 58.1% -5.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.756M $3.270M $2.899M
YoY Change 13.82% 17.07% -20.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $231.4K $500.0K $500.0K
YoY Change -53.71%
Total Long-Term Liabilities $231.4K $500.0K $500.0K
YoY Change -53.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.756M $3.270M $2.899M
Total Long-Term Liabilities $231.4K $500.0K $500.0K
Total Liabilities $3.987M $3.761M $3.400M
YoY Change 4.93% 34.62% -10.53%
SHAREHOLDERS EQUITY
Retained Earnings -$43.79M -$39.76M
YoY Change 51.31% 66.81%
Common Stock $7.346K $7.346K
YoY Change 321.7% 321.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.21M $27.13M $31.02M
YoY Change
Total Liabilities & Shareholders Equity $67.20M $30.89M $34.45M
YoY Change 117.47% 113.17% 77.7%

Cashflow Statement

Concept 2021 2020 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income -$16.92M -$4.030M -$3.906M
YoY Change 13.95% -3.59% -32.09%
Depreciation, Depletion And Amortization $5.357K $10.00K $0.00
YoY Change -65.68% 0.0% -100.0%
Cash From Operating Activities -$12.49M -$4.630M -$1.250M
YoY Change -5.04% -16.12% -71.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $48.54M $19.00M
YoY Change 63.14%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.89M 0.000 17.79M
YoY Change 63.91%
NET CHANGE
Cash From Operating Activities -12.49M -4.630M -1.250M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 48.89M 0.000 17.79M
Net Change In Cash 36.40M -4.630M 16.54M
YoY Change 118.27% -11.81% -482.87%
FREE CASH FLOW
Cash From Operating Activities -$12.49M -$4.630M -$1.250M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001472091
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Auditor Firm
AuditorFirmId
185
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37568
CY2021 dei Entity Registrant Name
EntityRegistrantName
PDS Biotechnology Corp
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4231384
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
25B Vreeland Road
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
CY2021 dei City Area Code
CityAreaCode
800
CY2021 dei Local Phone Number
LocalPhoneNumber
208-3343
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00033 per share
CY2021 dei Trading Symbol
TradingSymbol
PDSB
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
339715787
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28448612
CY2021 dei Auditor Name
AuditorName
KPMG LLP
CY2021 dei Auditor Location
AuditorLocation
Short Hills, New Jersey
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1597569
CY2021Q4 us-gaap Assets Current
AssetsCurrent
66840191
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
86
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
357611
CY2021Q4 us-gaap Assets
Assets
67197888
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1309403
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2187704
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1735322
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
258924
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
119904
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3756031
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3270450
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
231430
CY2021Q4 us-gaap Liabilities
Liabilities
3987461
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
9387
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
123904602
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60703562
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
63210427
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67197888
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
4346
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
55006
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11697707
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
432321
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29756502
CY2020 pdsb Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
70459
CY2020 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
19967
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-14847380
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27129576
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4074458
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48544998
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
344125
CY2021 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
35747
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-16918477
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
63210427
CY2021 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
0
CY2020 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-498185
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
70459
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1848416
CY2021Q4 pdsb Number Of Planned Clinical Trials Delayed
NumberOfPlannedClinicalTrialsDelayed
2
CY2021Q4 pdsb Number Of Planned Clinical Trials
NumberOfPlannedClinicalTrials
3
CY2021Q2 pdsb Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
4500000
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6088235
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.50
CY2021 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3361353
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65200000
CY2021 pdsb Common Stock Purchase Agreement Term
CommonStockPurchaseAgreementTerm
P30M
CY2019Q3 pdsb Common Stock Purchase Agreement Shares That Can Be Sold Percentage
CommonStockPurchaseAgreementSharesThatCanBeSoldPercentage
0.1999
CY2019Q3 pdsb Common Stock Purchase Agreement Shares That Can Be Sold Percentage
CommonStockPurchaseAgreementSharesThatCanBeSoldPercentage
0.1999
CY2019Q3 us-gaap Share Price
SharePrice
5.76
CY2019Q3 pdsb Stock Issued During Period Shares Equity Transaction
StockIssuedDuringPeriodSharesEquityTransaction
100654
CY2019Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
603924
CY2021Q4 pdsb Common Stock Purchase Agreement Cumulative Shares Sold
CommonStockPurchaseAgreementCumulativeSharesSold
0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
10000000
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.30
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000000
CY2020Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
11900000
CY2020Q3 pdsb Shelf Registration Statement Available For Future Sale
ShelfRegistrationStatementAvailableForFutureSale
100000000
CY2020Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6900000
CY2020Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.75
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19000000.0
CY2020Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
17100000
CY2021Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51700000
CY2021Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
48500000
CY2021Q4 pdsb Shelf Securities Available For Sale
ShelfSecuritiesAvailableForSale
29300000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
65242622
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
28839565
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
115420
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
115420
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
115334
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
109977
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
86
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5443
CY2021 us-gaap Depreciation
Depreciation
5357
CY2020 us-gaap Depreciation
Depreciation
15608
CY2019Q3 pdsb Operating Lease Percentage Of Remaining Payments Required To Be Paid To Terminate Lease
OperatingLeasePercentageOfRemainingPaymentsRequiredToBePaidToTerminateLease
0.50
CY2019Q3 pdsb Operating Lease Remaining Lease Payments
OperatingLeaseRemainingLeasePayments
665802
CY2019Q3 pdsb Operating Lease Number Of Installments For Remaining Lease Payment
OperatingLeaseNumberOfInstallmentsForRemainingLeasePayment
3
CY2021Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11200
CY2021Q4 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P40M
CY2021Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P20M
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
700000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0915
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
170839
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
98133
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
668764
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
241031
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
294986
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
239469
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2021Q4 pdsb Lessee Operating Lease Liability To Be Paid Year Five And Thereafter
LesseeOperatingLeaseLiabilityToBePaidYearFiveAndThereafter
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
534455
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
44101
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
490354
CY2020 pdsb Effective Income Tax Rate Reconciliation Sale Of Net Operating Loss Percent
EffectiveIncomeTaxRateReconciliationSaleOfNetOperatingLossPercent
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.018
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.028
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.023
CY2021 pdsb Effective Income Tax Rate Reconciliation Sale Of Net Operating Loss Percent
EffectiveIncomeTaxRateReconciliationSaleOfNetOperatingLossPercent
0.210
CY2021Q4 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
227400
CY2020Q4 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
204780
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
485400
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
219822
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1458310
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1310720
CY2021Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
16594
CY2020Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
0
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2187704
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1735322
CY2021Q4 pdsb Number Of Equity Based Compensation Plans
NumberOfEquityBasedCompensationPlans
3
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4074457
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
432321
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11800706
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
22831097
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
19757859
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3426561
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0053
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9750
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0049
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0039
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.65
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.14
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2021Q4 pdsb Number Of Votes For Each Share Of Common Stock
NumberOfVotesForEachShareOfCommonStock
1
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.130
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.067
CY2021 pdsb Effective Income Tax Rate Reconciliation Extraordinary Gain Percent
EffectiveIncomeTaxRateReconciliationExtraordinaryGainPercent
0.000
CY2020 pdsb Effective Income Tax Rate Reconciliation Extraordinary Gain Percent
EffectiveIncomeTaxRateReconciliationExtraordinaryGainPercent
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.089
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.045
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.271
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.016
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.211
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
5704791
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1374830
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1687123
CY2021Q4 pdsb Deferred Tax Assets Amortization Of Patents
DeferredTaxAssetsAmortizationOfPatents
35579
CY2020Q4 pdsb Deferred Tax Assets Amortization Of Patents
DeferredTaxAssetsAmortizationOfPatents
41695
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
4665
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
352642
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
719666
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
721024
CY2021Q4 pdsb Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
137838
CY2020Q4 pdsb Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
171543
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
15278
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
18098
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30616841
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30296704
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30516318
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30142744
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
100523
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
153960
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
100523
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
153960
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
100523
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
153960
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30500000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30100000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
400000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4500000
CY2021Q4 pdsb Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
185195
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
183372
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
35747
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
19967

Files In Submission

Name View Source Status
0001140361-22-012244-index-headers.html Edgar Link pending
0001140361-22-012244-index.html Edgar Link pending
0001140361-22-012244.txt Edgar Link pending
0001140361-22-012244-xbrl.zip Edgar Link pending
brhc10035378_10k.htm Edgar Link pending
brhc10035378_10k_htm.xml Edgar Link completed
brhc10035378_ex10-19.htm Edgar Link pending
brhc10035378_ex10-20.htm Edgar Link pending
brhc10035378_ex10-21.htm Edgar Link pending
brhc10035378_ex10-22.htm Edgar Link pending
brhc10035378_ex10-23.htm Edgar Link pending
brhc10035378_ex10-24.htm Edgar Link pending
brhc10035378_ex10-25.htm Edgar Link pending
brhc10035378_ex21-1.htm Edgar Link pending
brhc10035378_ex23-1.htm Edgar Link pending
brhc10035378_ex31-1.htm Edgar Link pending
brhc10035378_ex31-2.htm Edgar Link pending
brhc10035378_ex32-1.htm Edgar Link pending
brhc10035378_ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image0001.jpg Edgar Link pending
image00010.jpg Edgar Link pending
image00011.jpg Edgar Link pending
image0002.jpg Edgar Link pending
image0003.jpg Edgar Link pending
image0004.jpg Edgar Link pending
image0005.jpg Edgar Link pending
image0006.jpg Edgar Link pending
image0007.jpg Edgar Link pending
image0008.jpg Edgar Link pending
image0009.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pdsb-20211231.xsd Edgar Link pending
pdsb-20211231_cal.xml Edgar Link unprocessable
pdsb-20211231_def.xml Edgar Link unprocessable
pdsb-20211231_lab.xml Edgar Link unprocessable
pdsb-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending